Status: Not yet recruiting

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.

Participants needed: 200

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: May 28, 2026Locations: 1

Eligibility criteria

Participants must be 18 years of age or older, able to understand and give writt... [+11]

Stage IV (metastatic) breast cancer [+7]

Status: Recruiting

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS

Participants needed: 20

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 17, 2026Locations: 1

Eligibility criteria

Participants must have histologically or cytologically confirmed undifferentiate... [+16]

Prior treatment with immune checkpoint inhibitors (ICIs) [+46]

Status: Recruiting

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.

Participants needed: 34

Trial details

Phase: Phase 2Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 14, 2026Locations: 1

Eligibility criteria

Relapsed disease: progressive disease (PD) >60 days after cessation of prior the... [+16]

Within 14 days or at least 5 half-lives, whichever is less, of any investigation... [+16]

Status: Not yet recruiting

Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum

To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal cancer.

Participants needed: 20

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Apr 6, 2026Locations: 1

Eligibility criteria

Participants must have histologically or cytologically confirmed squamous cell c... [+25]

Has a history of documented severe dry eye syndrome, severe Meibomian gland dise... [+21]